Compile Data Set for Download or QSAR
maximum 50k data
Found 31 Enz. Inhib. hit(s) with all data for entry = 929
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199539((1r,5s,7s)-9-methyl-3-oxa-9-azabicyclo [3.3.1]nona...)
Affinity DataIC50:  0.462nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199092((1r,5s,7s)-3-oxa-9-azabicyclo[3.3.1]nonan- 7-yl 1-...)
Affinity DataIC50:  0.510nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199498(US10125145, Cpd. No. 11 | US9670229, 11 | n-((1r,5...)
Affinity DataIC50:  0.600nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM299207((1R,5S,7S)-3-oxa-9-azabicyclo [3.3.1]nonan-7-yl 1-...)
Affinity DataIC50:  0.620nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199522((1r,5s,7s)-3-oxa-9-azabicyclo[3.3.1]nonan- 7-yl 1-...)
Affinity DataIC50:  0.650nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199485(US10125145, Cpd. No. 10 | US9670229, 10 | n-((1r,5...)
Affinity DataIC50:  0.650nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199504(5-fluoro-n-((1r,5s,7s)-9-methyl-3-oxa-9- azabicycl...)
Affinity DataIC50:  0.662nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199484((1r,5s,7s)-9-methyl-d3-3-oxa-9-azabicyclo [3.3.1]n...)
Affinity DataIC50:  0.680nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199096(US10125145, Cpd. No. 4 | US9670229, 4 | n-((1r,5s,...)
Affinity DataIC50:  0.690nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199501(5-fluoro-n-((1r,5s,7s)-9-methyl-3-oxa-9- azabicycl...)
Affinity DataIC50:  0.720nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199541((1r,5s,7s)-9-methyl-3-oxa-9-azabicyclo [3.3.1]nona...)
Affinity DataIC50:  0.745nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199513((1r,5s,7s)-3-oxa-9-azabicyclo[3.3.1] nonan-7-yl 1-...)
Affinity DataIC50:  0.75nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199094((1r,5s,7s)-3-oxa-9-azabicyclo[3.3.1]nonan- 7-yl 1-...)
Affinity DataIC50:  0.810nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199500(US10125145, Cpd. No. 12 | US9670229, 12 | n-((1r,5...)
Affinity DataIC50:  0.882nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199091((1r,5s,7s)-3-oxa-9-azabicyclo[3.3.1]nonan- 7-yl 1-...)
Affinity DataIC50:  0.950nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199094((1r,5s,7s)-3-oxa-9-azabicyclo[3.3.1]nonan- 7-yl 1-...)
Affinity DataIC50:  0.960nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199524((1r,5s,7s)-3-oxa-9-azabicyclo[3.3.1]nonan- 7-yl 1-...)
Affinity DataIC50:  1.01nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199092((1r,5s,7s)-3-oxa-9-azabicyclo[3.3.1]nonan- 7-yl 1-...)
Affinity DataIC50:  1.10nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199521((1r,5s,7s)-3-oxa-9-azabicyclo[3.3.1] nonan-7-yl 1-...)
Affinity DataIC50:  1.10nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199518((1r,5s,7s)-3-oxa-9-azabicyclo[3.3.1] nonan-7-yl 1-...)
Affinity DataIC50:  1.20nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM299216(N-((1R,5S,7S)-9-methyl-3-oxa-9- azabicyclo[3.3.1]n...)
Affinity DataIC50:  1.34nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199544(3-(3-(((1r,5s,7s)-9-methyl- 3-oxa-9-azabicyclo[3.3...)
Affinity DataIC50:  1.36nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199527((1r,5s,7s)-3-oxa-9-azabicyclo[3.3.1]nonan- 7-yl 1-...)
Affinity DataIC50:  1.39nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199533((1r,5s,7s)-9-methyl-3-oxa-9- azabicyclo[3.3.1]nona...)
Affinity DataIC50:  1.44nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199520((1r,5s,7s)-3-oxa-9-azabicyclo[3.3.1] nonan-7-yl 1-...)
Affinity DataIC50:  1.5nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM299220((1R,5S,7S)-9-methyl-3-oxa-9- azabicyclo[3.3.1]nona...)
Affinity DataIC50:  2.01nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199538((1r,5s,7s)-9-methyl-3-oxa-9- azabicyclo[3.3.1]nona...)
Affinity DataIC50:  2.04nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199512((1r,5s,7s)-3-oxa-9-azabicyclo[3.3.1] nonan-7-yl 1-...)
Affinity DataIC50:  2.5nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199110((1r,5s,7s)-9-methyl-d3-3-oxa-9-azabicyclo [3.3.1]n...)
Affinity DataIC50:  2.86nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM299221((1R,5S,7S)-3-oxa-9-azabicyclo [3.3.1]nonan-7-yl 1-...)
Affinity DataIC50:  3.68nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM199542((1r,5s,7s)-9-methyl-3-oxa-9-azabicyclo [3.3.1]nona...)
Affinity DataIC50: >1.00E+3nMAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent